FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Davidson Matt						Issuer Name and Ticker or Trading Symbol Verrica Pharmaceuticals Inc. [VRCA] Date of Earliest Transaction (Month/Day/Year)									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner				
(Last)	(Fir	,	/liddle			01/16/2019									Offic belov	er (give title w)		ther elow)	specify
C/O VERRICA PHARMACEUTICALS INC. 10 NORTH HIGH STREET, SUITE 200						4. If Amendment, Date of Original Filed (Month/Day/Year))	or Joint/Group Filing (Che			
(Street) WEST CHESTE	R PA	. 1	9380												Form filed by More than One Reporting Person				
(City)	(Sta	ate) (Z	Zip)																
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of \$	2. Transaction Date (Month/Day/		2A. Deemed Execution Date, if any (Month/Day/Year)				Disposed	rities Acquired (A ed Of (D) (Instr. 3,			l Secur	icially d	6. Owners Form: Dir (D) or Indirect (I (Instr. 4)	ect	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
								Code	v	Amount	(A) (D)	or Pr	ice	Repo Trans		((
Common	Stock	01/16/20	19				S ⁽¹⁾		600	D	\$	10.29(2))24,272	D				
Common	01/17/20	19			S ⁽¹⁾		2,181	D	\$	10.18	3) 3,0	3,022,091							
Common Stock 01/18/2)19			S ⁽¹⁾		2,984	D	\$	10.32	3,019,107		D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execu if any			action (Instr.	of Deri Secu Acqu (A) o Disp	oosed 0) tr. 3, 4	6. Date Expirati (Month/	on D Day/	Year) Securities Underlying Derivative Security (In 3 and 4) Am or Nur Expiration Securities		nt of ities lying ative ity (Ins 4)	tr.	Price f erivative ecurity nstr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owner Form: Direct or Ind (I) (Ins 4)	(D) rect	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

- 1. These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 22, 2018.
- 2. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from \$10.20 to \$10.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 3. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from \$10.00 to \$10.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 4. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from \$10.25 to \$10.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

/s/ Mark Ballantyne, Attorneyin-Fact 01/18/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.